146 related articles for article (PubMed ID: 26691221)
1. Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis.
Vogel TJ; Jeon C; Karlan B; Walsh C
Gynecol Oncol; 2016 Feb; 140(2):285-8. PubMed ID: 26691221
[TBL] [Abstract][Full Text] [Related]
2. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Vogel TJ; Goodman MT; Li AJ; Jeon CY
Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
[TBL] [Abstract][Full Text] [Related]
3. A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
Garcia C; Yao A; Camacho F; Balkrishnan R; Cantrell LA
Gynecol Oncol; 2017 Aug; 146(2):346-350. PubMed ID: 28499649
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O
Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307
[TBL] [Abstract][Full Text] [Related]
5. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.
Champer M; Huang Y; Hou JY; Tergas AI; Burke WM; Hillyer GC; Ananth CV; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2018 Jan; 148(1):19-27. PubMed ID: 29153542
[TBL] [Abstract][Full Text] [Related]
6. Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study.
Doll KM; Pinheiro LC; Reeve BB
Gynecol Oncol; 2017 Feb; 144(2):348-353. PubMed ID: 27988047
[TBL] [Abstract][Full Text] [Related]
7. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
[TBL] [Abstract][Full Text] [Related]
8. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer outcomes: Predictors of early death.
Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA
Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531
[TBL] [Abstract][Full Text] [Related]
10. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer.
Joseph N; Clark RM; Dizon DS; Lee MS; Goodman A; Boruta D; Schorge JO; Del Carmen MG; Growdon WB
Gynecol Oncol; 2015 Jun; 137(3):401-5. PubMed ID: 25839911
[TBL] [Abstract][Full Text] [Related]
11. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.
Wright JD; Herzog TJ; Neugut AI; Burke WM; Lu YS; Lewin SN; Hershman DL
Obstet Gynecol; 2012 Oct; 120(4):871-81. PubMed ID: 22996105
[TBL] [Abstract][Full Text] [Related]
12. Racial disparities in the treatment of advanced epithelial ovarian cancer.
Howell EA; Egorova N; Hayes MP; Wisnivesky J; Franco R; Bickell N
Obstet Gynecol; 2013 Nov; 122(5):1025-1032. PubMed ID: 24104782
[TBL] [Abstract][Full Text] [Related]
13. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer.
Thrall MM; Gray HJ; Symons RG; Weiss NS; Flum DR; Goff BA
Gynecol Oncol; 2011 Dec; 123(3):461-6. PubMed ID: 21945309
[TBL] [Abstract][Full Text] [Related]
15. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
16. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
Thrall MM; Gray HJ; Symons RG; Weiss NS; Flum DR; Goff BA
Gynecol Oncol; 2011 Jul; 122(1):100-6. PubMed ID: 21496889
[TBL] [Abstract][Full Text] [Related]
17. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer.
Fairfield KM; Murray K; Lucas FL; Wierman HR; Earle CC; Trimble EL; Small L; Warren JL
J Clin Oncol; 2011 Oct; 29(29):3921-6. PubMed ID: 21911719
[TBL] [Abstract][Full Text] [Related]
18. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
[TBL] [Abstract][Full Text] [Related]
19. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA
Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
Miao Y; Li S; Yan Q; Li B; Feng Y
Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
